Swedish biopharmaceutical company Xbrane Biopharma AB (Xbrane) (STO:XBRANE) on Friday reported a loss of SEK32.4m, or SEK2.24 per share, for the third quarter of 2019, from July 2019 to September 2019.
This was a decline over profit of SEK 60.1m, or EPS of SEK9.49, in the third quarter of 2019.
Revenues for the quarter amounted to SEK0.0m, a decline over SEK2.4m in previous third quarter.
Also, Xbrane added that it has secured financing for the Xplore study up until top-line data is received from all patients
In addition, a rights issue that began in the second quarter of 2019 was completed and brought in SEK91.1m to the company, before transaction costs.
Xbrane develops and produces biosimilars. It has a patented protein production platform for development of biosimilars.
(EUR1.00=SEK10.66)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development